Engaged urokinase receptors enhance tumor breast cell migration and invasion by upregulating αvβ5 vitronectin receptor cell surface expression

International Journal of Cancer

Volumn 102, Issue 6, 2002, Pages 562-571

  Silvestri, Immacolata ^a   Cattani, Immacolata Longanesi ^a   Franco, Paola ^b   Pirozzi, Giuseppe ^a   Botti, Gerardo ^a   Stoppelli, Maria Patrizia ^b   Carriero, Maria Vincenza ^a,c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Cell invasion; Soluble antagonist; Urokinase; Vitronectin receptor

Indexed keywords

ANTINEOPLASTIC AGENT; CALPHOSTIN; HISTIDINE UROKINASE; MATRIGEL; MITHRAMYCIN; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VITRONECTIN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CELL; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; RECEPTOR UPREGULATION; REGULATORY MECHANISM; TUMOR BIOPSY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL MOVEMENT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHAVBETA3; MIDDLE AGED; NEOPLASM INVASIVENESS; RECEPTORS, CELL SURFACE; UP-REGULATION; URINARY PLASMINOGEN ACTIVATOR;

EID: 0037146757     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10744     Document Type: Article

References (46)

1. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanism of metastasis. Cancer 1997;80:1529-37.
2. Liotta LA, Kohn EC. The microenvironment of the tumor-host interface. Nature 2001;411:375-9.
3. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997;9:714-24.
4. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinasetype plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997;72:1-22.
5. Dano K, Romer J, Nielsen BS, Bijorn S, Pyke C, Rygaard J, Lund LR. Cancer invasion and tissue remodeling - Cooperation of protease systems and cell types. APMIS 1999;107:120-7.
6. Carriero MV, Franco P, Del Vecchio S, Massa O, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res 1994;54:5445-54.
7. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WLJ, Klijn JGM. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000;60:636-43.
8. Del Vecchio S, Stoppelli MP, Carriero MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiuto G, Esposito G, Salvatore M. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: Comparison with urokinase levels. Cancer Res 1993;53:3198-206.
9. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA. Regulation of integrin function by the urokinase receptor. Science 1996;273:1551-5.
10. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. Urokinase receptor and fibronectin receptor regulate the ERK (MAPK) to p38 (MAPK) activity ratios that determine carcinoma cell proliferation and dormancy in vivo. Mol Biol Cell 2001;12:863-79.
11. hck activation state is a molecular switch between myelomonocytic cell motility and adherence. EMBO J 1999;18:3013-23.
12. Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S. Urokinase receptor antagonist inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996;56:2428-34.
13. Magdolen V, Burgle M, de Prada NA, Schmiedeberg N, Riemer C, Schroeck F, Kellermann J, Degitz K, Wilhelm OG, Schmitt M, Kessler H. Cyclo 19,31[D-Cys19]-uPA 19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87). Biol Chem 2001;382:1197-205.
14. 138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility. J Cell Biol 1997;137:779-91.
15. Franco P, Massa O, Garcia-Rocha M, Chiaradonna F, Iaccarino C, Correas I, Mendez E, Avila J, Blasi F, Stoppelli MP. Protein kinase C-dependent in vivo phosphorylation of prourokinase leads to the formation of a receptor competitive antagonist. J Biol Chem 1998;273:27734-40.
16. Carriero MV, Franco P, Gargiulo L, Vocca I, Cito L, Fontana L, Iaccarino C, Del Pozzo G, Guardiola J, Stoppelli MP. Inhibition of receptor-dependent urokinase signaling by specific Ser to Glu substitutions. Biol Chem 2002;383:107-13.
17. Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, Blasi F. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA 2002;99:1359-64.
18. Xue W, Mizukami I, Todd RF III, Petty HR. Urokinase-type plasminogen activator receptors associate with β1 and β3 integrins of fibrosarcoma cells: Dependence on extracellular matrix components. Cancer Res 1997;57:1682-9.
19. Simon DI, Wei Y, Zhang L, Rao NK, Xu H, Chen Z, Liu Q, Rosenberg S, Chapman HA. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J Biol Chem 2000;275:10028-34.
20. Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: Coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000;12:613-20.
21. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999;285:1028-32.
22. 1 phase of the cell cycle. Mol Cell 2001;8:115-27.
23. Schwartz MA. Integrins, oncogenes and anchorage-independence. J Cell Biol 1997;139:575-8.
24. Zutter MM, Santoro SA, Staatz WD, Tsung YL. Re-expression of the α2β1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc Natl Acad Sci USA 1995;92:7411-5.
25. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damasky C, Bissell MJ. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997;137:231-45.
26. Morini M, Mottolese M, Ferrari N, Ghiorzo F, Buglioni S, Mortarini R, Noonan DM, Natali PG, Albini A. The alpha3beta1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer 2000;87:336-42.
27. Reinartz J, Schafer B, Batrla R, Klein CE, Kramer MD. Plasmin abrogates αvβ5-mediated adhesion of a human keratinocyte cell line (HaCaT) to vitronectin. Exp Cell Res 1995;220:274-82.
28. Yebra M, Parry GCN, Strombland S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA, Requirement of receptor-bound urokinase-type plasminogen for integrin αvβ5-directed cell migration. J Biol Chem 1996;271:29393-9.
29. Carriero MV, Del Vecchio S, Capozzoli M, Franco P, Fontana L, Zannetti A, Botti G, D'Aiuto G, Salvatore M, Stoppelli MP. Urokinase receptor interacts with αvβ5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res 1999;59:5307-14.
30. Zannetti A, Del Vecchio S, Carriero MV, Fonti R, Franco P, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M. Coordinate up-regulation of Sp1 DNA binding activity and urokinase receptor expression in breast carcinoma. Cancer Res 2000;60:1546-51.
31. Montuori N, Mattiello A, Mancini A, Santoli M, Taglialatela P, Caputi M, Rossi G, Ragno P. Urokinase-type plasminogen activator up-regulates the expression of its cellular receptor through a post-transcriptional mechanism. FEBS Lett 2001;508:379-84.
32. Shetty S, Idell S. Urokinase induces expression of its own receptor in Beas2B lung epithelial cells. J Biol Chem 2001;276:24549-56.
33. Wayner EA, Orlando RA, Cheresh DA. Integrins αvβ3 and αvβ5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J Cell Biol 1991;113:919-29.
34. Black MM, Speer FD. Nuclear structure in cancer tissues. Surg Gynecol Obstet 1957;105:97-102.
35. Bradford MA. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the prinicple of protein-dye binding. Anal Biochem 1976;72:248-254.
36. Kook YH, Adamski J, Zelent A, Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 1994;13:3983-91.
37. Tsuj T, Kawada Y, Kai-Murozono M, Komatsu S, Han SA, Takeuchi K, Mizushima H, Miyazaki K, Irimura T. Regulation of melanoma cell migration and invasion by laminin-5 and alpha3beta1 integrin (VLA-3). Clin Exp Metastasis 2002;19:127-34.
38. Carriero MV, Del Vecchio S, Franco P, Potena MI, Chiaradonna, F, Botti G, Stoppelli MP, Salvatore M. Vitronectin binding to urokinase receptor in breast carcinoma. Clin Cancer Res 1997;3:1299-308.
39. Feng X, Teitelbaum SL, Quiroz ME, Cheng SL, Lai CF, Avioli LV, Ross FP. Sp1/Sp3 and PU.1 differentially regulate β5 integrin gene expression in macrophages and osteoblasts. J Biol Chem 2000;275:8331-40.
40. Lai CF, Feng X, Nishimura R, Teitelbaum SL, Avioli LV, Ross FP, Cheng SL. Transforming growth factor-β up-regulates the β5 integrin subunit expression via Sp1 and Smad signaling, J Biol Chem 2000;275:36400-6.
41. Johnson MD, Torri JA, Lippman ME, Dickson RB. Regulation of motility and protease expression in PKC-mediated induction of MCF-7 breast cancer cell invasiveness. Exp Cell Res 1999:247:105-13.
42. Zambruno G, Marchisio PC, Marconi A, Vaschieri C, Melchiorri A, Giannetti A, De Luca M. Transforming growth factor-β1 modulates β1 and β5 integrin receptors and induces de novo expression of the αvβ6 heterodimer in normal human keratinocytes. Implication for wound healing. J Cell Biol 1995;129:853-65.
43. Togel F, Datta C, Badbaran A, Kroger N, Renges H, Gieseking F, Janicke F, Zander A, Kruger W. Urokinase-like plasminogen activator receptor expression on disseminated breast cancer cells. J Haematol Ther Stem Cell Res 2001;10:141-5.
44. Ashkenas J, Muschler J, Bissel MJ. The extracellular matrix in epithelial biology: Shared molecules and common themes in distant phyla. Dev Biol 1996;180:433-44.
45. Nip J, Rabbani SA, Shibata HR, Brodt P. Coordinated expression of the vitronectin urokinase-type plasminogen activator receptor in metastatic melanoma cells. J Clin Invest 1995;95:2096-103.
46. Brower V. Tumor angiogenesis - New drugs on the block. Nat Biotechnol 1999;17:963-8.